Pharmaceutical industry
Merck before taking over the billion of cancer specialists
The pharmaceutical company wants to strengthen his business with cancer medicines with a billion-dollar purchasing. Talks with a US company are already far. With the deal, Merck would iron out his own weaknesses.
The Darmstadt Merck Group stands in front of a billion-dollar takeover of the US Cancer Specialist SpringWorks Therapeutics. Both companies were in “far advanced conversations” about a possible purchase, said Merck. With the approaching billion dollar deal, the DAX group would manage the greatest purchase in years and strengthen its business with cancer medication.
Previously, the “Wall Street Journal” had reported that a transaction in volume of around 3.5 billion US dollars (3.08 billion euros) was planned. However, no final decision has yet been made and no legally connecting agreement has been concluded, emphasized Merck. Based on a price, the companies speak around $ 47 per springwork share.
Springworks based in the US state of Connecticut was split off by the pharmaceutical giant Pfizer in 2017. The company focuses on therapies against rare tumors and blood cancer and already has a medication approved in the United States for the treatment of progressive soft tubes.
Merck under pressure after medication flops
Merck’s pharmaceutical division recently grew solidly again. The group is under pressure to launch new medication. Several hopes of hope that were supposed to rinse billions of billions in the health insurers had failed in clinical studies.
Merck had therefore increasingly relied on the marketing of their medication with other companies, but recently also took care of take over again.
The last major takeover in 2019 with the U.S. helmet conductor Versum Versum made material worth around 5.8 billion euros. The greatest purchase in the company’s history was the US laboratory supplier Sigma-Aldrich, which Merck took over in 2015 for 13 billion euros.
dpa
Source: Stern
